Nuclear medicine therapy increases survival for patients with colorectal cancer liver metastases

November 6, 2013, Society of Nuclear Medicine

For patients who fail to respond to current first-line and second-line treatments for colorectal cancer liver metastases (also known as salvage patients), radioembolization with Y-90 microspheres could extend survival according to new research published in the November issue of The Journal of Nuclear Medicine. A systematic review conducted by researchers showed that approximately 50 percent of salvage patients have an overall survival of more than 12 months after this nuclear medicine therapy.

Colorectal cancer is the third most commonly diagnosed type of cancer worldwide in men and the second in women, and it is also the third most common cause of death. In approximately 50 percent of patients, metastases to the liver are present at diagnosis or during follow-up, which account for a large portion of morbidity and mortality in patients.

A structured review was performed by researchers to gather all available evidence on radioembolization for the specific group of patients with . "Although quite some reviews are printed on the subject of radioembolization, we felt that a structured and comprehensive review on survival and response data for these patients was lacking," said Charlotte E.N.M. Rosenbaum, PhD, lead author of the study "Radioembolization for Treatment of Salvage Patients with Colorectal Cancer Liver Metastases: A Systemic Review."

Researchers reviewed a total of 13 articles on Y-90 radioembolization as a monotherapy and 13 articles on Y-90 radioembolization as a combined with chemotherapy. Among the studies, disease control rates (i.e., complete response, partial response and stable disease) ranged from 29-90 percent in the monotherapy studies, which involved 901 patients. In the studies in which Y-90 radioembolization was combined with chemotherapy, involving 472 patients, disease control rates ranged from 59-100 percent.

"From the studies included in this , survival proportions of approximately 50 percent were found. Therefore, in this group of salvage colorectal cancer liver metastases who otherwise have no regular treatment options and a life expectancy of less than six months, Y-90 radioembolization seems to be a hopeful treatment option," noted Rosenbaum.

She continued, "Our paper shows all published data on this subject from the first randomized trial onwards. Furthermore, we have determined 12-month survival proportions for all included articles to provide a better overview and to better allow for comparisons. Finally, this overview of the literature shows which topics have not been the focus of much research and may thus be interesting for further work."

Explore further: Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer

More information: "Radioembolization for Treatment of Salvage Patients with Colorectal Cancer Liver Metastases: A Systemic Review" The Journal of Nuclear Medicine, 2013. interactive.snm.org/index.cfm? … D=1110&FileID=236548

Related Stories

Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer

November 6, 2013
Long term results of the randomized phase III EORTC intergroup trial 40983 were recently reported in The Lancet Oncology. The observed 4.1% difference in overall survival at five years for patients with initially resectable ...

Adding cetuximab to chemotherapy enables patients with advanced colorectal cancer, liver metastasis to undergo surgery

April 8, 2013
New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have ...

Radioembolization improves chance of survival for liver cancer patients

August 22, 2011
Analysis revealed survival for patients with hepatocellular carcinoma (HCC) is achievable using 90Y-resin microsphere radioembolization. The analysis conducted at multiple centers across Europe showed that the procedure is ...

EORTC BOS 2 trial opens for patients with resectable liver metastases from colorectal cancer

June 4, 2013
Colorectal cancer (CRC) is the second most frequent cause of cancer-related mortality in both Europe and the United States. Treatment for patients with resectable hepatic metastases from colorectal cancer consists of surgery ...

Liver metastases and its prognostic significance in men with metastatic prostate cancer

May 31, 2012
Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.